Editorial companion

What stands out

Stéphane Bancel says Moderna’s personalized mRNA cancer vaccine, being developed with Merck, could work across multiple tumor types, and he framed that as an answer to a core uncertainty about Moderna’s roadmap. The clip stands out because the claim comes from the company’s CEO, not a scientist hedging the language, and because it ties Moderna’s long-term narrative to a large and well-known oncology partner rather than to a single trial result. That framing gives the market a cleaner story to price even if clinical proof is still to come.